Targeting of tumor-associated gangliosides with antibodies affects signaling pathways and leads to cell death including apoptosis

Apoptosis

Volumn 20, Issue 5, 2015, Pages 679-688

  Horwacik, Irena ^a   Rokita, Hanna ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Antibody; Apoptosis; Cancer; Cell death; Ganglioside; Glycosphingolipid

Indexed keywords

ANTINEOPLASTIC AGENT; GANGLIOSIDE; MONOCLONAL ANTIBODY;

ANIMAL; APOPTOSIS; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; GANGLIOSIDES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84939962940     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-015-1103-7     Document Type: Article

References (62)

1. Yu RK, Tsai YT, Ariga T, Yanagisawa M (2011) Structures, biosynthesis, and functions of gangliosides-an overview. J Oleo Sci 60:537-544
2. Tettamanti G (2004) Ganglioside/glycosphingolipid turnover: new concepts. Glycoconj J 20:301-317
3. Flangea C, Serb A, Sisu E, Zamfir AD (2011) Chip-based nanoelectrospray mass spectrometry of brain gangliosides. Biochim Biophys Acta 1811:513-535. doi: 10.1016/j.bbalip.2011.06.008
4. Ghiulai RM, Sarbu M, Vukelić Ž, Ilie C, Zamfir AD (2014) Early stage fetal neocortex exhibits a complex ganglioside profile as revealed by high resolution tandem mass spectrometry. Glycoconj J 31:231-245
5. Willison HJ, Yuki N (2002) Peripheral neuropathies and anti-glycolipid antibodies. Brain 125:2591-2625
6. Ariga T, McDonald MP, Yu RK (2008) Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease - a review. J Lipid Res 49:1157-1175. doi: 10.1194/jlr.R800007-JLR200
7. Sandhoff K, Harzer K (2013) Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis. J Neurosci 33:10195-10208. doi: 10.1523/JNEUROSCI.0822-13.2013
8. Ryan JM, Rice GE, Mitchell MD (2013) The role of gangliosides in brain development and the potential benefits of perinatal supplementation. Nutr Res 33:877-887. doi: 10.1016/j.nutres.2013.07.021
9. Furukawa K, Ohmi Y, Ohkawa Y, Tokuda N, Kondo Y, Tajima O, Furukawa K (2011) Regulatory mechanisms of nervous systems with glycosphingolipids. Neurochem Res 36:1578-1586. doi: 10.1007/s11064-011-0494-2
10. Ohmi Y, Tajima O, Ohkawa Y, Yamauchi Y, Sugiura Y, Furukawa K, Furukawa K (2011) Gangliosides are essential in the protection of inflammation and neurodegeneration via maintenance of lipid rafts: elucidation by a series of ganglioside-deficient mutant mice. J Neurochem 116:926-935. doi: 10.1111/j.1471-4159.2010.07067.x
11. Prinetti A, Loberto N, Chigorno V, Sonnino S (2009) Glycosphingolipid behaviour in complex membranes. Biochim Biophys Acta 1788:184-193. doi: 10.1016/j.bbamem.2008.09.001
12. Simons K, Gerl MJ (2010) Revitalizing membrane rafts: new tools and insights. Nat Rev Mol Cell Biol 11:688-699. doi: 10.1038/nrm2977
13. Janich P, Corbeil D (2007) GM1 and GM3 gangliosides highlight distinct lipid microdomains within the apical domain of epithelial cells. FEBS Lett 581:1783-1787
14. Todeschini AR, Dos Santos JN, Handa K, Hakomori SI (2007) Ganglioside GM2-tetraspanin CD82 complex inhibits met and its cross-talk with integrins, providing a basis for control of cell motility through glycosynapse. J Biol Chem 282:8123-8133
15. Lopez PH, Schnaar RL (2009) Gangliosides in cell recognition and membrane protein regulation. Curr Opin Struct Biol 19:549-557. doi: 10.1016/j.sbi.2009.06.001
16. Sorice M, Matarrese P, Tinari A, Giammarioli AM, Garofalo T, Manganelli V, Ciarlo L, Gambardella L, Maccari G, Botta M, Misasi R, Malorni W (2009) Raft component GD3 associates with tubulin following CD95/Fas ligation. FASEB J 23:3298-3308. doi: 10.1096/fj.08-128140
17. Matarrese P, Garofalo T, Manganelli V, Gambardella L, Marconi M, Grasso M, Tinari A, Misasi R, Malorni W, Sorice M (2014) Evidence for the involvement of GD3 ganglioside in autophagosome formation and maturation. Autophagy 10:750-765. doi: 10.4161/auto.27959
18. Todeschini AR, Hakomori SI (2008) Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochim Biophys Acta 1780:421-433
19. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ (1982) GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med 155:1133-1147
20. Longee DC, Wikstrand CJ, Månsson JE, He X, Fuller GN, Bigner SH, Fredman P, Svennerholm L, Bigner DD (1991) Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas. Acta Neuropathol 82:45-54
21. Livingston PO, Hood C, Krug LM, Warren N, Kris MG, Brezicka T, Ragupathi G (2005) Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy. Cancer Immunol Immunother 54:1018-1025
22. Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, Titze U, Leuchte K, Landmeier S, Hotfilder M, Dirksen U, Hardes J, Gosheger G, Juergens H, Rossig C (2012) The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer 106:1123-1133. doi: 10.1038/bjc.2012.57
23. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, Perez R, Ando S (1996) Gangliosides expressed in human breast cancer. Cancer Res 56:5165-5171
24. Alvarez-Rueda N, Desselle A, Cochonneau D, Chaumette T, Clemenceau B, Leprieur S, Bougras G, Supiot S, Mussini JM, Barbet J, Saba J, Paris F, Aubry J, Birklé S (2011) A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity. PLoS ONE 6:e25220. doi: 10.1371/journal.pone.0025220
25. Hettmer S, Ladisch S, Kaucic K (2005) Low complex ganglioside expression characterizes human neuroblastoma cell lines. Cancer Lett 225:141-149
26. Hettmer S, McCarter R, Ladisch S, Kaucic K (2004) Alterations in neuroblastoma ganglioside synthesis by induction of GD1b synthase by retinoic acid. Br J Cancer 91:389-397
27. Birklé S, Zeng G, Gao L, Yu RK, Aubry J (2003) Role of tumor-associated gangliosides in cancer progression. Biochimie 85:455-463
28. Shibuya H, Hamamura K, Hotta H, Matsumoto Y, Nishida Y, Hattori H, Furukawa K, Ueda M, Furukawa K (2012) Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. Cancer Sci 103:1656-1664. doi: 10.1111/j.1349-7006.2012.02344.x
29. Yan Q, Bach DQ, Gatla N, Sun P, Liu JW, Lu JY, Paller AS, Wang XQ (2013) Deacetylated GM3 promotes uPAR-associated membrane molecular complex to activate p38 MAPK in metastatic melanoma. Mol Cancer Res 11:665-675. doi: 10.1158/1541-7786.MCR-12-0270-T
30. Lee HC, Wondimu A, Liu Y, Ma JS, Radoja S, Ladisch S (2012) Ganglioside inhibition of CD8+ T cell cytotoxicity: interference with lytic granule trafficking and exocytosis. J Immunol 189:3521-3527
31. Wondimu A, Liu Y, Su Y, Bobb D, Ma JS, Chakrabarti L, Radoja S, Ladisch S (2014) Gangliosides drive the tumor infiltration and function of myeloid-derived suppressor cells. Cancer Res 74:5449-5457. doi: 10.1158/0008-5472.CAN-14-0927
32. Liu Y, Wondimu A, Yan S, Bobb D, Ladisch S (2014) Tumor gangliosides accelerate murine tumor angiogenesis. Angiogenesis 17:563-571. doi: 10.1007/s10456-013-9403-4
33. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323-5337. doi: 10.1158/1078-0432.CCR-09-0737
34. Ahmed M, Cheung NK (2014) Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett 588:288-297. doi: 10.1016/j.febslet.2013.11.030
35. Daniotti JL, Vilcaes AA, Torres Demichelis V, Ruggiero FM, Rodriguez-Walker M (2013) Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches. Front Oncol 3:306. doi: 10.3389/fonc.2013.00306
36. Vázquez AM, Rodrèguez-Zhurbenko N, López AM (2012) Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry. Front Oncol 2:170. doi: 10.3389/fonc.2012.00170
37. Horwacik I, Rokita H (2012) Application of molecular mimicry to target GD2 ganglioside. In: Shimada H (ed) Neuroblastoma - present and future, InTech, Rijeka, pp. 251-271. doi: 10.5772/30020
38. Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schönfeld K, Tonn T, Huebener N, Lode HN, Koehl U, Wels WS (2012) NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med 16:569-581. doi: 10.1111/j.1582-4934.2011.01343.x
39. Bjerkvig R, Engebraaten O, Laerum OD, Fredman P, Svennerholm L, Vrionis FD, Wikstrand CJ, Bigner DD (1991) Anti-GM2 monoclonal antibodies induce necrosis in GM2-rich cultures of a human glioma cell line. Cancer Res 51:4643-4648
40. Nakamura K, Hanibuchi M, Yano S, Tanaka Y, Fujino I, Inoue M, Takezawa T, Shitara K, Sone S, Hanai N (1999) Apoptosis induction of human lung cancer cell line in multicellular heterospheroids with humanized antiganglioside GM2 monoclonal antibody. Cancer Res 59:5323-5330
41. Roque-Navarro L, Chakrabandhu K, de León J, Rodríguez S, Toledo C, Carr A, de Acosta CM, Hueber AO, Pérez R (2008) Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther 7:2033-2041. doi: 10.1158/1535-7163.MCT-08-0222
42. Dippold WG, Knuth A, Meyer zum Büschenfelde KH (1984) Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res 44:806-810
43. Yoshida S, Fukumoto S, Kawaguchi H, Sato S, Ueda R, Furukawa K (2001) Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res 61(10):4244-4252
44. Kowalczyk A, Gil M, Horwacik I, Odrowaz Z, Kozbor D, Rokita H (2009) The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Cancer Lett 281:171-182. doi: 10.1016/j.canlet.2009.02.040
45. Horwacik I, Durbas M, Boratyn E, Wȩgrzyn P, Rokita H (2013) Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells. Cancer Lett 341:248-264. doi: 10.1016/j.canlet.2013.08.018
46. Cochonneau D, Terme M, Michaud A, Dorvillius M, Gautier N, Frikeche J, Alvarez-Rueda N, Bougras G, Aubry J, Paris F, Birklé S (2013) Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo. Cancer Lett 333:194-204. doi: 10.1016/j.canlet.2013.01.032
47. Hedberg KM, Dellheden B, Wikstrand CJ, Fredman P (2000) Monoclonal anti-GD3 antibodies selectively inhibit the proliferation of human malignant glioma cells in vitro. Glycoconj J 17:717-726
48. Liu B, Wu Y, Zhou Y, Peng D (2014) Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells. PLoS ONE 9:e93576. doi: 10.1371/journal.pone.0093576
49. Retter MW, Johnson JC, Peckham DW, Bannink JE, Bangur CS, Dresser K, Cai F, Foy TM, Fanger NA, Fanger GR, Woda B, Rock KL (2005) Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts. Cancer Res 65:6425-6434
50. Doronin II, Vishnyakova PA, Kholodenko IV, Ponomarev ED, Ryazantsev DY, Molotkovskaya IM, Kholodenko RV (2014) Ganglioside GD2 in reception and transduction of cell death signal in tumor cells. BMC Cancer. doi: 10.1186/1471-2407-14-295
51. Aixinjueluo W, Furukawa K, Zhang Q, Hamamura K, Tokuda N, Yoshida S, Ueda R, Furukawa K (2005) Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J Biol Chem 280:29828-29836
52. Cazet A, Lefebvre J, Adriaenssens E, Julien S, Bobowski M, Grigoriadis A, Tutt A, Tulasne D, Le Bourhis X, Delannoy P (2010) GD3 synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation. Mol Cancer Res 8:1526-1535. doi: 10.1158/1541-7786.MCR-10-0302
53. Cazet A, Bobowski M, Rombouts Y, Lefebvre J, Steenackers A, Popa I, Guérardel Y, Le Bourhis X, Tulasne D, Delannoy P (2012) The ganglioside G(D2) induces the constitutive activation of c-Met in MDA-MB-231 breast cancer cells expressing the G(D3) synthase. Glycobiology 22:806-816. doi: 10.1093/glycob/cws049
54. Rahmaniyan M, Qudeimat A, Kraveka JM (2012) Bioactive sphingolipids in neuroblastoma. In: Shimada H (ed) Neuroblastoma - present and future, InTech, Rijeka, pp.153-184. doi: 10.5772/27830
55. Hayashida N, Inouye S, Fujimoto M, Tanaka Y, Izu H, Takaki E, Ichikawa H, Rho J, Nakai A (2006) A novel HSF1-mediated death pathway that is suppressed by heat shock proteins. EMBO J 25:4773-4783
56. Yoshida S, Kawaguchi H, Sato S, Ueda R, Furukawa K (2002) An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation. Jpn J Cancer Res 93:816-824
57. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ (1985) Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82:1242-1246
58. Uttenreuther-Fischer MM, Huang CS, Reisfeld RA, Yu AL (1995) Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients. Cancer Immunol Immunother 41:29-36
59. Kushner BH, Kramer K, Modak S, Cheung NK (2011) Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. J Clin Oncol 29:1168-1174. doi: 10.1200/JCO.2010.28.3317
60. Gilman AL, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, Sternberg A, Hank JA, Seeger R, Reaman GH, Sondel PM (2009) Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 27:85-91. doi: 10.1200/JCO.2006.10.3564
61. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324-1334. doi: 10.1056/NEJMoa0911123
62. Hernández AM, Rodríguez N, González JE, Reyes E, Rondón T, Griñán T, Macías A, Alfonso S, Vázquez AM, Pérez R (2011) Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J Immunol 186:3735-3744. doi: 10.4049/jimmunol.1000609